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Summary Tumour growth is dependent on angiogenesis. Vascular endothelial growth factor (VEGF) is a secreted endothelial cell-specific
cytokine. VEGF is angiogenic in vivo and it also acts as a vascular permeability factor. VEGF is overexpressed in many skin disorders
characterized by angiogenesis and increased vascular permeability. We investigated VEGF expression in 22 primary cutaneous melanomas,
33 melanoma metastases and six naevocellular naevi using immunohistochemistry. VEGF accumulated on the vascular endothelia in the
normal dermis, suggesting that a constitutive low level of VEGF expression may regulate skin vessel function under normal physiological
conditions. No VEGF was detected in the cells of naevocellular naevi or normal dermis. In contrast, 32% of the primary and 91% of the
metastatic melanomas contained melanoma cells staining for VEGF. Expression of VEGF was more frequent in metastases than in primary
melanomas (P <0.0001). Tumour-infiltrating inflammatory cells expressed VEGF in all melanomas. A high number of VEGF-expressing
inflammatory cells was associated with high VEGF expression in melanoma cells (P= 0.003). Our results suggest that VEGF is up-regulated
during the course of melanoma progression and dissemination and that tumour-infiltrating cells expressing VEGF may contribute to the
progression of melanoma.
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Angiogenesis, the formation of new capillaries, is an important
component in many biological processes and also pathological
conditions, such as rheumatoid arthritis, diabetic retinopathy, wound
healing and neoplastic diseases (reviewed in Folkman, 1995). The
growth of all solid tumours is dependent on the formation of new
blood vessels. During tumorigenesis, the quiescent vasculature can
become activated to grow new capillaries in response to an appro-
priate stimulus (reviewed in Hanahan and Folkman, 1996). One
such stimulus is vascular endothelial growth factor (VEGF), which
is a secreted, dimeric 46-kDa protein active as an endothelial cell-
specific mitogen and as a vascular permeability factor. VEGF
expression has been detected in a large variety ofmalignant human
tumours, and ithas been concluded thatVEGFhas animportant role
in tumour biology and in the process of tumour angiogenesis
(reviewed in Dvorak et al, 1995; Ferrara, 1995). VEGF mRNA has
also been detected in metastatic melanoma cells in cerebral
melanoma metastases (Hatva et al, 1995).
Progression of melanoma is supposed to be associated with an
angiogenic response, and several histological studies have shown
an increase in vascular structures in malignant melanoma, which is
not the case in common naevocellular naevi (reviewed in Denijn
and Ruiter, 1993). Expression of VEGF in mouse VEGF cDNA-
transected melanoma cells is associated with increased tumour
growth, angiogenesis and experimental metastasis in vivo in a
nude mouse model (Claffey et al, 1996). This suggests a role for
VEGF as a positive regulatory stimulus in angiogenesis, progres-
sion and dissemination of malignant melanoma. The aim of the
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present study was to investigate the expression ofVEGF in normal
dermis, naevocellular naevi and in primary and metastatic
melanoma and to study the relationship between VEGFexpression
and tumour microvessel density, patient survival and otherclinico-
pathological variables.
MATERIALS AND METHODS
Patients and tissue samples
The study includes six patients with a common naevocellular
naevus and 55 randomly selected patients with histologically
diagnosed malignant melanoma treated with surgery and
chemotherapy or chemoimmunotherapy in Helsinki University
Central Hospital, during the time period from 1989 to 1995. The
prognostic significance ofVEGF expression was investigated in a
series of33 patients with a lymph node metastasis from malignant
melanoma. Twenty ofthe patients with metastatic melanoma were
male and 13 were female; age at the time of surgery ranged from
30 to 84 years (median 56 years). All patients with metastatic
disease were followed up until death or for at least 4 years, as
calculated from the surgical removal ofthe lymph node metastasis.
The overall 2-year survival was 35% and 4-year survival 24%.
Determination of VEGF expression
VEGF expression was determined using a mouse monoclonal anti-
human VEGF antibody (MAB293, IgG2b, R&D Research, MN,
USA) raised against the 165 amino acid species ofthe polypeptide.
The 5-,um frozen sections were rehydrated, incubated for 30 min in
0.3% hydrogen peroxidase in methanol at room temperature and
for 20 min in 5% normal horse serum at room temperature. The
sections were incubatedovernight at4°C with the primary antibody
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Table 1 VEGF expression in malignant melanoma
No expression Low Moderate High
(0%) (1-4%) (5-9%) (10-60%)
Proportion of VEGF-expressing melanoma cells
Primary cutaneous melanomas (n = 22) n (%) 15 (68) 6 (27) 1 (5) 0 (0)
Melanoma metastases (n = 33) n (%) 3 (9) 16 (48) 7 (21) 7 (21)
Numberof VEGF-expressing inflammatory cells
Primary cutaneous melanomas (n = 22) n (%) - 16 (73) 6 (27)a -
Melanoma metastases (n = 33) n (%) - 22 (67) 11 (33)a
aRefers of moderate or high level of expression.
at a dilution of 1:24. A subsequent incubation for 30 min in
biotinylated anti-mouse serum was followed by a 30-min incuba-
tion using reagents ofthe Vectastain Elite ABC kit (Vector labora-
tories, Burlingame, CA, USA). Peroxidase activity was developed
with 3-amino-9-ethyl carbazole (Sigma, St Louis, MO, USA) for
10 min. Finally, the sections were stained with haematoxylin for 5
min. Negative controls were performed by omitting the primary
antibody or by using irrelevant primary antibodies. Following the
staining procedures, all samples wereexaminedby atrained pathol-
ogist without knowledge of patient outcome or other variables.
The expression of VEGF was scored as a percentage of stained
melanoma cells. The amount of inflammatory cells within the
tumour that stained for VEGF was graded as minimal, moderate or
marked. Tumour necrosis was recorded as absent or present.
Assessment of intratumoral microvessel density
The microvessel densities ofthe tumour samples were determined
using two established vascular markers, the von Willebrand factor
(vWF) and CD31 (PECAM-1). After incubating the slides for
20 min with 2% normal horse serum, the endothelial cells were
stained with a monoclonal anti-vWF antibody (Dako, Denmark)
using a dilution of 1:50, or monoclonal anti-CD31 antibody
(Dako) using a dilution of 1:50, incubating overnight at +4'C. A
subsequent incubation for 30 min in biotinylated anti-mouse
serum was followed by a 30-min incubation using reagents of the
Vectastain Elite ABC kit (Vector), developed with 3-amino-9-
ethyl carbazole (Sigma) for 10 min and counterstained with
haematoxylin for 5 min. Vascularity was defined as previously
described (Weidner et al, 1991) by counting the number ofvessels
per a 400x magnification field in the areas with the highest
vascular density ('vascular hotspots'). A minimum of five fields
was counted and the three highest counts were averaged. The
guidelines recommended by Gasparini and Harris (1995) were
followed.
Assessment of intratumoral inflammatory infiltrate
The inflammatory infiltrates in the melanoma metastases were
assessed using an anti-CD45RB antibody. This antibody reacts
with B- and T-cells, monocytes, macrophages and weakly with
granulocytes. After incubating the slides for 20 min with 2%
normal horse serum, the slides were stained with a monoclonal
mouse anti-human CD45RB antibody (clone PD7/26, Dako) using
a dilution of 1:500, incubating for 1 h at room temperature. A
subsequent incubation for 30 min in biotinylated anti-mouse
serum was followed by a 30-min incubation using the reagents of
the Vectastain Elite ABC kit (Vector), developed with 3-amino-9-
ethyl carbazole (Sigma) for 10 min and counterstained with
haematoxylin for 5 min. The number ofCD45-positive inflamma-
tory cells within the tumour was graded as minimal, moderate or
marked.
Statistical analysis
The Mann-Whitney test and Spearman rank correlation coeffi-
cient test were used to examine the associations between different
variables. Frequency tables were analysed with the chi-squared
test. Cumulative survival was estimated with the Kaplan-
Meier product-limit method. The Mantel-Cox log-rank test was
used to compare survival between different groups. All P-values
are two-tailed.
RESULTS
VEGF in common naevocellular naevi and normal
dermis
No immunoreactivity for VEGF was detected in the cells of
naevocellular naevi or cells of the histologically normal dermis.
Immunostaining for VEGF was observed in endothelial cells of
the microvessels in all samples (Figure lA and B).
VEGF in primary cutaneous melanomas
Cytoplasmic staining of melanoma cells for VEGF was observed
in 7 (32%) out ofthe 22 primary cutaneous melanomas. One ofthe
samples showed strong VEGF expression in 5% of the melanoma
cells of the tumour whereas, in the six other primary melanomas
expressing VEGF, the number of VEGF-positive melanoma cells
was small, only 1-2% of the melanoma cells (Table 1, Figure IC
and D). Cytoplasmic staining for VEGF was observed in a part of
the tumour-infiltrating inflammatory cells in all samples exam-
ined. Constant staining for VEGF was also found in the endothe-
lial cells oftumour microvessels (arrows in Figure IC).
VEGF in melanoma metastases
Cytoplasmic staining of melanoma cells for VEGF was observed
in 30 out ofthe 33 melanoma metastases (91%). The proportion of
the stained melanoma cells ranged from 0% to 60% (median 3%,
mean 9%; Table 1, Figure IE and F). Thus, the proportion of
tumours with melanoma cells staining for VEGF was higher in the
metastases than in the primary cutaneous melanomas (30 out of33
vs 7 out of 22, P < 0.0001). A part of the tumour-infiltrating
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Figure 1 Immunohistochemical staining of the VEGF polypeptide in (A and B) a naevocellular naevus and histologically normal dermis, in (C and D) a primary
cutaneous melanoma and in (E and F) a lymph node metastases from malignant melanoma. (E) A metastasis with a high percentage of VEGF-expressing
melanoma cells. (F) The median melanoma cell VEGF expression in metastases in the present series (3%). Note the immunostaining of capillary endothelia for
VEGF (arrows in A-C and F). VEGF immunoreactivity is also observed in (G and H) tumour-infiltrating inflammatory cells of a melanoma metastasis. (H) Detail
of G. Scale bar= 50,m
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inflammatory cells stained for VEGF in all metastases examined
(Figure IG and H). A constant staining for VEGF was also
found in the endothelial cells of tumour microvessels (arrows in
Figure IF).
A high amount of VEGF-expressing tumour-infiltrating inflam-
matory cells in a metastasis was found to be associated with a high
percentage ofVEGF-expressing melanoma cells (P = 0.003, tested
minimal vs moderate or marked number ofVEGF-positive inflam-
matory cells). Expression of VEGF in melanoma cells or in
inflammatory cells was not associated with the total number of
inflammatory cells in the tumour, as assessed using the anti-CD45
antibody (P > 0.1, tested minimal vs moderate or marked number
of CD45-positive inflammatory cells).
VEGF expression and microvessel density
The microvessel counts obtained by staining for vWF and CD31
were strongly associated (P = 0.0003). However, the anti-CD31
antibody constantly stained more vascular structures than the anti-
vWF antibody (median 33, range 15-67 vs median 26, range 9-56
respectively; P = 0.02). No associations were found between the
microvessel densities obtained using the anti-CD31 antibody or
the anti-vWF antibody and melanoma cell VEGF expression
(P> 0.1 for both comparisons, tested < median vs > median).
VEGF expression and clinicopathological parameters
Among the primary cutaneous melanomas (n = 22), no differences
could be observed in the VEGF expression when thin and thick
primary melanomas were compared (P> 0.1, tested < median
vs > median, 1 mm). The association between VEGF expression in
lymph node metastases (n = 33) and prognosis was studied in a
univariate survival analysis. The median (3%) and the highest
quartile (10%) percentages of melanoma cell VEGF expression
were used as cut-off values. No associations between VEGF
expression and overall survival were found in the analyses (P> 0.1
for both comparisons). Similarly, no associations were found
between the extent of tumour necrosis (tested present, n = 16 vs
absent, n = 17) or the size of the metastasis (tested < median
vs > median, 30 mm) and melanoma cell VEGF expression
(P > 0.1 for both comparisons).
DISCUSSION
Studies in human melanoma cell lines xenografted to nude mice
have suggested that VEGF plays a role in angiogenesis and
progression of malignant melanoma (Potgens et al, 1995; Claffey
et al, 1996). We observed strong cytoplasmic staining for VEGF in
melanoma cells in as many as 91% ofthe melanoma metastases. In
contrast to metastatic melanoma, only 32% of the primary cuta-
neous melanomas had detectable VEGF expression in melanoma
cells and only one of the primary melanomas showed staining in
more than 5% of the melanoma cells. No immunoreactivity for
VEGF could be detected in cells of naevocellular naevi or the
histologically normal dermis.
We found immunostaining for VEGF in endothelial cells in both
malignant and benign samples. Similar findings have been
published for tumour blood vessels. These studies showed by
immunohistochemistry that vascular endothelial cells stained
strongly for VEGF but did not express detectable levels of VEGF
mRNA by in situhybridization, indicating thatimmunohistochem-
ical staining of tumour vessels with antibodies to VEGF peptides
reflects binding ofVEGF secreted by adjacent cells (Duorak et al,
1991; Brown et al, 1993).
Low amounts of VEGF mRNA have also been detected in the
normal skin (Brown et al, 1992; Weninger et al, 1996). Ourfinding
of accumulation of VEGF on the vascular endothelium in the
histologically normal dermis suggests that a constitutive low level
VEGF expression may regulate skin vessel function under normal
physiological conditions. Overexpression of VEGF has been
reported in skin disorders that are characterized by angiogenesis
and increased vascular permeability (Brown et al, 1995a). VEGF
is strongly expressed by epidermal keratinocytes in wound healing
and psoriasis, both accompanied by angiogenesis and increased
microvascular permeability (Brown et al, 1992; Detmar et al,
1994). In delayed hypersensitivity skin reactions, which are also
characterized by microvascular hyperpermeability, in situ
hybridization revealed that the mRNAs encoding VEGF were
strikingly overexpressed in keratinocytes ofthe epidermis (Brown
et al, 1995b). Weninger et al (1996) recently detected VEGF
mRNA in the cells of common warts, squamous cell carcinomas
and keratoacanthomas using in situ hybridization, and the VEGF
mRNA expression was paralleled by VEGF immunostaining.
The angiogenetic activity and increased vascular permeability
observed in the previously described disorders was accompanied
by strong up-regulation or overexpression of VEGF mRNA when
analysed by in situ hybridization. Because of the inability of
immunohistochemistry to detect small amounts of soluble
proteins, the VEGF immunoreactivity that we found in the few
primary melanomas and in the majority of the metastatic
melanomas probably reflects a population of melanoma cells
expressing high levels of VEGF. Recent data indicate that the
amount of VEGF may be crucial for its function, as studies with
heterozygous and homozygous VEGF-deficient transgenic mice
suggest a tight dose-dependent regulation of embryonic vessel
development by VEGF (Carmeliet et al, 1996; Ferrara et al, 1996).
We found VEGF-expressing tumour-infiltrating inflammatory
cells in every melanoma sample studied. In line with our results,
lymphocytes infiltrating human prostate or bladder cancers, periph-
eral blood T-lymphocytes and also scattered mononuclear cells infil-
trating the dermis in delayed hypersensitivity skin reactions have
been found to express VEGF (Brown et al, 1995b; Freeman et al,
1995). Ourresults indicate that up-regulation ofVEGF expression in
metastatic melanoma cells is associated with elevation in the number
of tumour-infiltrating inflammatory cells expressing VEGF. The
results suggest a possible role for the VEGF-expressing tumour-
infiltrating inflammatory cells in angiogenesis. Interestingly, in mice
inoculated with melanoma cells, doxorubicin induced tumour
growth retardation and a decrease in peritumoral vascularity that was
associated with the degree of myelosuppression monitored by
counting bone marrow cells, circulating leucocytes and peritoneal
macrophages (Gutman et al, 1994). The decrease in peritumoral
vascularity might in part result from a possible direct effect of
the drug on endothelial cells. Nevertheless, it is attractive to
speculate that in addition to the direct anti-tumour effects, cancer
chemotherapy may produce retardation of tumour growth by
producing myelosuppression and hence inhibition of inflammatory
cell-induced, VEGF-mediated tumour angiogenesis.
VEGF has been shown to be induced by hypoxia in vitro
(Shweiki et al, 1992) and in vivo (Banai et al, 1994). When
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melanoma cell lines expressing in vitro high or low levels of
VEGF mRNA were xenografted into nude mice, the difference
between VEGF mRNA expression levels disappeared in vivo. In
all xenografts, equally high levels of VEGF mRNA were found,
independent of the VEGF expression in the parental cell line
(Potgens et al, 1995). Similarly, in xenografted tumours in nude
mice in vivo, concomitantly with invasion of new blood vessels
and restoration of normoxia in the implanted tumour, VEGF
expression was gradually down-regulated to a constitutive low
level ofexpression, representing the output ofnon-stressed tumour
cells (Shweiki et al, 1995). Expression of VEGF in our series did
not correlate with the primary melanoma thickness, microvessel
density or patient survival in metastatic disease; this may be a
reflection of the same phenomenon when hypoxia and possibly
also other factors regulate the expression of VEGF in a reversible
manner. Therefore, tumours with a dense microvasculature may
sometimes express only low levels of VEGF, and tumours with a
low microvessel density may display high levels ofVEGF biosyn-
thesis at a time when the vascular supply becomes inadequate.
However, the prognostic significance of VEGF expression in
primary melanoma requires further study.
Taken together, our results suggest that a constitutive low level
expression of VEGF may regulate skin vessel function under the
normal physiological conditions. The results are compatible with
up-regulation of VEGF expression during melanoma tumorigen-
esis, progression and dissemination, suggesting an elementary role
for VEGF in the angiogenic response necessary for melanoma
growth and metastasis formation. The hyperpermeability of the
newly formed blood vessels caused by VEGF (discussed in
Dvorak et al, 1995) may be an essential factor in the metastatic
process ofthe primary cutaneous melanoma. Expression ofVEGF
in tumour-infiltrating inflammatory cells may indicate that these
cells contribute to angiogenesis and progression of malignant
melanoma. Ourobservations also suggest that VEGF is a potential
target for anti-angiogenic tumour therapy in melanoma.
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